Category: St. Jude Medical
St. Jude strides forward in the race for deep-brain stimulation with FDA approval to expand its DBS study for patients with major depressive disorders who find no relief from other treatments.
St. Jude Medical Inc. (NYSE:STJ) won U.S. Food & Drug Administration approval to expand its BROADEN study of deep-brain stimulation for major depressive disorders, allowing a maximum of 20 sites across the U.S. to enroll up to 125 patients.
Is St. Jude poised to release its Merlin remote monitoring platform in India soon?
Boston Scientific plans to add 250 workers to its operations in Costa Rica.
Boston Scientific Corp. (NYSE:BSX) plans to hire 250 new employees for its manufacturing operation in Latin America, according to a report from Costa Rica.
The Natick, Mass.-based medical device maker is expanding its engineering, production, quality control and process development roles in Heredia, just outside the capital city of San José. BSX also has a plant in Alajuela, Costa Rica, according to Inside Costa Rica.
The latest heart implant study from the Journal of the American Medical Assn. creates more uncertainty about proper use of pricey cardiac devices.
MASSDEVICE ON CALL — Uncertainty surrounding the use of cardiac stents and angioplasty balloons may lead to a market backlash against the devices and their makers.
At least 4 percent and up to 12 percent of percutaneous coronary interventions may be implanted outside of industry-recommended guidelines, according to an article published in the Journal of the American Medical Assn. yesterday.
A new study questioning the appropriateness of cardiac stents and angioplasty balloons may have a ripple effect on The Street.
A footnote in a study published in the Journal of the American Medical Assn. about percutaneous coronary interventions may have a ripple effect on Wall Street.
The study gathered data on more than 500,000 PCIs conducted at more than 1,000 U.S. hospitals between July 2009 and September 2010. The researchers determined the appropriateness of each procedure based on the 2009 coronary revascularization appropriate use criteria, a whitesheet generated and endorsed by medical professional societies in 2009 amid growing debate over proper use of PCIs.
Omar Amirana, a partner at the Boston, Mass.-based life science VC firm Oxford Biosciences, jumps ship for Allied Minds.
Omar Amirana, a partner at Oxford Biosciences, a life sciences VC firm that manages more than $1 billion in capital, will be pulling up anchor and moving over to Allied Minds, a "a private equity-funded innovation company."
Allied Minds, which bills itself as "a holding company that creates subsidiary companies and supports them with capital, management, and shared services," has offices in Boston and Los Angeles. The firm has over $250 million in assets and specializes in developing technology created at universities and research labs.
Results from St. Jude's trials of its electrical stimulation therapy for migraines will likely be enough to win CE Mark approval in the European Union, but falls short of FDA requirements for the U.S.
St. Jude Medical (NYSE:STJ) wanted to show the world last week that its new chronic migraine treatment was good enough to win regulatory approval.